Stock BJTRF BEIJING TONG REN TANG CHINESE MEDICINE COMPANY LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Beijing Tong Ren Tang Chinese Medicine Company Limited OTC Markets

Equities

BJTRF

HK0000145638

Market Closed - OTC Markets
Other stock markets
 09:30:04 2024-04-01 am EDT 		5-day change 1st Jan Change
0.6484 USD -56.77% Intraday chart for Beijing Tong Ren Tang Chinese Medicine Company Limited -.--% -56.48%
Jun. 07 Beijing Tong Ren Tang Chinese Medicine Company Limited Approves Final Dividend for the Year Ended December 31, 2023 CI
May. 13 Tong Ren Tang Chinese Medicine Appoints CEO MT

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • The company's attractive earnings multiples are brought to light by a P/E ratio at 11.41 for the current year.
  • The company is one of the best yield companies with high dividend expectations.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
  • The group usually releases upbeat results with huge surprise rates.

Weaknesses

  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • Over the past twelve months, analysts' opinions have been revised negatively.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
BEIJING TONG REN TANG CHINESE MEDICINE COMPANY LIMITED Stock Beijing Tong Ren Tang Chinese Medicine Company Limited
-56.48% 966M -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+55.95% 811B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+43.62% 640B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.98% 353B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.08% 333B
B-
ABBVIE INC. Stock AbbVie Inc.
+9.05% 302B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.30% 246B
B+
ROCHE HOLDING AG Stock Roche Holding AG
+2.41% 225B
A+
NOVARTIS AG Stock Novartis AG
+12.47% 218B
B-
AMGEN INC. Stock Amgen Inc.
+8.91% 168B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 3613 Stock
  4. BJTRF Stock
  5. Ratings Beijing Tong Ren Tang Chinese Medicine Company Limited